Anti-Osteoporosis
And Fracture Healing Market, by Drug Class (Bisphosphonates (Alendronate,
Risedronate, Ibandronate, Zoledronic acid), Hormone replacement therapy
(Estrogen, Progestin, Others), Monoclonal Antibodies (Denosumab, Romosozumab),
Anabolic Agents (Alendronate, Teriparatide), and Others), by Route of Administration
(Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook,
and Opportunity Analysis, 2018 – 2026
Osteoporosis involves a
condition, which results when the rate of bone tissue regeneration is much less
than its breakdown, making the bones porous. Osteoporosis is more prevalent in
female, where more cases occur after menopause due to decrease in estrogen
hormone levels. In osteoporosis, the strength and structure of bones is
affected, which increases the probability of occurrence of fractures,
especially in hip region, wrists, and spine. An X-ray based scanning method,
Dual Energy X-ray Absorptiometry (DEXA) or bone densitometry, is used for
diagnosis of the condition. Osteoporosis has no clear symptoms, although is
characterized by spine weakening and joint pain.
Anti-Osteoporosis and Fracture
Healing Market Drivers
In the recent past, various
regulatory bodies such as European Medicines Agency (EMA), U.S. Food and Drug
Administration (FDA), Medicines and Healthcare Products Regulatory Agency
(MHRA), and others approved new drugs for treatment of osteoporosis. Approval
and launch of such new drugs are expected to drive global Anti-Osteoporosis and
Fracture Healing Market growth over the forecast period. For instance, in April
2017, Radius Health Inc., a biopharmaceutical company, received approval from
U.S. Food and Drug Administration (FDA) for TYMLOS (abaloparatide) injection,
for treating postmenopausal women with osteoporosis who are at high risk of
fracture. This drug reduces the occurrence of spinal cord and peripheral
skeleton fractures in postmenopausal women.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2525
Furthermore, key players are
launching new treatment methods for osteoporosis in the market. For instance,
in January 2016 Ahn-Gook Pharmaceutical Co., Ltd., a South Korea based
pharmaceutical company, received approval from the Korean Ministry of Food and
Drug Safety (MFDS) for marketing of Binosto buffered alendronate in Korea.
Alendronate reduces bone loss and buffering reduces the exposure of stomach and
esophagus to acidified alendronate. Such new product launches are expected to
fuel global Anti-Osteoporosis and Fracture Healing Market growth over the
forecast period.
Anti-Osteoporosis and Fracture Healing
Market Regional Analysis
North America anti-osteoporosis
and fracture healing market is expected to witness significant growth over the
forecast period owing to new product launches. For instance, in September 2018,
Zydus Pharma Inc. received approval from U.S. Food and Drug Administration
(FDA) for launch of Risedronate Sodium delayed release tablets in America, a
drug used for osteoporosis treatment in postmenopausal women.
In April 2018 Amgen Inc., an
American biopharmaceutical company, received approval from Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
for marketing of Prolia (denosumab) in Europe. Denosumab is used for treating
bone loss associated with prolonged systemic glucocorticoid therapy in patients
who are at increased risk of fracture. This is expected to drive the Europe
anti-osteoporosis and fracture healing market growth over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/anti-osteoporosis-and-fracture-healing-market-2525
In January 2018 Amgen Inc. and
UCB S.A announced receiving approval for marketing of Evenity (romosozumab)
drug in Japan by Japanese Ministry of Health, Labor and Welfare. Evenity is a
bone forming agent which performs dual role of increasing bone formation and
reducing bone resorption leading to reduced risk of fracture. These factors are
expected to support global Anti-Osteoporosis and Fracture Healing Market growth
over the forecast period.
Anti-Osteoporosis and Fracture
Healing Market Restraints
Bisphosphonate pills, a commonly
used medication for osteoporosis are not well absorbed in the stomach and are
involved with side effects such as stomach upset and heartburn. In addition to
this, increased awareness regarding osteoporosis, especially in women, has
resulted in consumption of calcium and vitamin rich diet and adapting
physiotherapeutic measures for prevention of occurrence of osteoporosis. These
factors are expected to restrain global Anti-Osteoporosis and Fracture Healing
Market growth over the forecast period.
Anti-Osteoporosis and Fracture
Healing Market Key Players
Some of the key players operating
in the anti-osteoporosis and fracture healing market are Radius Health Inc.,
Pfizer Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc., Merck & Co.,
Inc., F. Hoffman-La Roche AG, Eli, Lilly and Company Limited, and PhytoHealth
Corporation.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2525
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment